Jorge Benitez retired from Accenture in 2014 as chief executive of North America. He had primary responsibility for Accenture's business and operations in North America, including developing and executing the company's business strategy, delivering client service and driving its growth in the region. Prior to this role, Mr. Benitez served as the chief operating officer for products, the largest of Accenture's five operating groups. During his five years in that role, he led Accenture's global business across a wide set of consumer-relevant industry groups, including; Automotive;  Air Freight & Travel Services; Consumer Goods & Services; Industrial Equipment; Infrastructure & Transportation Services; Life Sciences; and Retail. He has also served as the executive sponsor for several of Accenture's largest clients. Mr. Benitez was selected in 2005 as one of the Top 100 Most Influential Hispanics in the United States. 

Bart Sichel, executive vice president and chief marketing officer at Burlington Stores, has been instrumental in shaping the strong bond between Burlington, a national off-price retailer, and LLS -- a relationship that has generated more than $32 million for blood cancer research and patient services since 2001. His interest and passion for LLS is also deeply personal: His son is a leukemia survivor and in 2005 he lost his father to lymphoma.  In 2011, Sichel joined the executive leadership team at Burlington.  He is part of a team that has created a growth trajectory for the company, taken it public, and significantly expanded Burlington's enterprise equity valuation. Prior to joining Burlington, Sichel was a principal at McKinsey & Company, where he specialized in marketing and e-commerce for clients in a wide range of industries. It was his work with the firm's social sector office that strengthened his passion for making a difference in non-profit settings. Sichel received a bachelor's degree in political science and economics from Vassar College and an MBA from Columbia University. 

Ralph Lawson is the executive vice president and chief financial officer of Baptist Health South Florida, Inc. Baptist Health owns six hospitals and 21 satellite outpatient centers, and is the largest private employer in Miami-Dade County. Baptist operates in three counties with over 14,000 employees, and has been recognized as one of the 100 Best Employers in America for the last eight years by Fortune Magazine. Lawson earned a bachelor of science degree from the University of Colorado and a master degree in business administration from The Wharton School of Finance, University of Pennsylvania. He also serves as chairman of the Board of Catholic Health Services and is the former National Chair of the Healthcare Financial Management Association (HFMA). 

Kathleen Meriwether is the Americas Life Sciences Leader for Ernst & Young LLP’s Forensic and Integrity practice. She specializes in assisting health sciences companies with global risks and compliance assessments and regulatory compliance analysis. She works closely with management teams, compliance officers and counsel to identify compliance and enforcement risks, determine potential vulnerabilities and recommend solutions from business and operational perspectives. Prior to joining Ernst & Young, she served as an assistant U.S. attorney in the U.S. Attorney’s Office for the Eastern District of Pennsylvania. She previously spent more than 16 years with Bristol-Myers Squibb Company in a number of legal, regulatory affairs and compliance positions, including division counsel for the Oncology and Immunology franchise.

Bill Behnke is the founder and president of The Behnke Group, founded in 2005. He is a senior executive with extensive background in direct sales, marketing, sales management, and business development, with a specialization in the health care market. He has more than 15 years of experience selling to CEOs, CFOs, CMOs, and boards of directors of health insurance companies and hospitals, and has significant success raising capital from venture capital firms, private equity firms, and accredited private investors. Behnke has been instrumental in opening doors; most recently he has recruited and supported the last two Men of the Year candidates. 

Peter Brock has been developing commercial real estate in the New York and Florida markets since 1975. For the past 10 years, he's been a principal in Brock Development and has developed major retail projects in the Florida area. Brock founded two land and development funds that have invested in commercial real estate in Florida, Texas, Arizona, Colorado, Tennessee, New Mexico and California. He has served on the investment committee of those funds for the past four years. He is the founder of Brock Services Corporation, a hotel management company. Brock assists with donor development by personally sharing history and speaking at LLS events. Brock graduated with a bachelor's degree in economics from the University of Pennsylvania's Wharton School of Finance & Commerce; and holds a master of business administration degree from the Columbia Graduate School of Business. 

Mr. Callow is a founder and managing partner of Boston Millennia Partners. Prior to forming Boston Millennia Partners, he co-founded Boston Capital Ventures in 1982 and is a partner in four of its investment partnerships. He also worked as a senior consultant at Braxton Associates, an international strategic planning firm. His primary clients were Fortune 100 multinational companies where he advised senior management on strategic planning and implementing merger and acquisition strategies. Prior to his activity in the management consulting business, he worked in sales and marketing for Tymshare, Inc., a venture funded and subsequent public company in the cloud and remote computing sector. Mr. Callow currently manages investments in CardioMems, Inc, a cardiovascular heart sensor device for the treatment of congestive heart failure and Arthrosurface, Inc., a developer and manufacturer of advanced orthopedic devices and COTA, Inc. a cancer tracking and outcomes analytics company. He chairs LLS's Therapeutic Acceleration Program Committee and is on the Board of Overseers at Tufts University Medical School as well as the Tufts Technology Development & Commercialization Advisory Board. Mr. Callow is a graduate of Tufts University and holds an MBA from the Amos Tuck School at Dartmouth College.

Renzo Canetta, M.D. has more than 35 years of clinical and regulatory cancer research experience at Bristol-Myers Squibb. At the forefront of cancer research, he has seen firsthand how innovation has transformed cancer treatment. His experience includes direct patient care, diagnosis and experimental treatment of cancers that affect blood, bone marrow and lymph nodes, as well as solid tumors, methodology of clinical trials and new drug development. He has held multiple leadership roles, including head of Clinical Cancer Research, head of Development on the Life Cycle Management team and head of Regulatory Oncology Research Policy. Dr. Canetta and his team developed 16 new drugs to treat cancer and two to treat viral infections, and received approval of more than 50 regulatory dossiers for additional indications and formulations. Dr. Canetta retired from Bristol-Myers Squibb in August, 2015.

Casey Cunningham, M.D. is the chief scientific officer of Santé Ventures, a venture capital fund focused on creating and investing in companies in healthcare and life sciences. Dr. Cunningham received his fellowship training in oncology and hematology at Harvard Medical School, where he subsequently served on the faculty. He was also one of the founding members of the Division of Experimental Medicine at the Brigham & Women’s Hospital in Boston. Dr. Cunningham received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. He returned to Texas in 1999 as the Associate Director of the Mary Crowley Cancer Research Center in Dallas, a position he held until 2007. He joined Santé Ventures shortly after its founding. He has served in operating roles in Terapio, Molecular Templates and Beta Cat Pharmaceuticals and has served on the Boards of Terapio Corp., Molecular Templates, Lyric Pharmaceuticals, AbVitro and Mirna Therapeutics.

William S. Dalton, Ph.D., M.D., is the founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. Dr. Dalton is the past president, CEO & center director of Moffitt Cancer Center. Prior to that role, Dr. Dalton was dean of the University of Arizona, College of Medicine. He is interested in the development of personalized cancer care and patient-centered outcomes research. Dr. Dalton's basic and translation research interests focus on molecular mechanisms of drug resistance and drug discovery in hematologic malignancies. He has more than 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine. 

Christopher R. Flowers, M.D., is professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He is a member of the Emory Stem Cell and Bone Marrow Transplant team and Director of the Emory Lymphoma Program. His clinic focuses on specialized care for patients with lymphoid malignancies and early phase clinical trials. Dr. Flowers is a member of InterLymph, an international collaboration of experts in lymphoma epidemiology that is focused on finding the causes for lymphoma and co-leader of the Lymphoma Epidemiology of Outcome (LEO) Cohort Study, the largest study in the US of lymphoma patients. The Lymphoma Program at Emory has been a key contributor in clinical trials that have led to FDA approval of new drugs for cancer patients. Dr. Flowers also has been instrumental in developing national guidelines for the management of cancer patients with the American Society of Clinical Oncology, the American College of Radiology, and the American Cancer Society. He is a Fellow of the American Society of Clinical Oncology and a member of the American Society of Clinical Investigation. Dr. Flowers graduated from Stanford University from the human biology and humanities honors programs. He remained at Stanford where he completed medical school and received a master’s degree in medical information sciences. After medical school, he completed an internal medicine residency at the University of Washington. He continued his research training in Seattle through the Robert Wood Johnson Clinical Scholars Program and oncology fellowship at the Fred Hutchinson Cancer Research Center.

Janice L. Gabrilove, M.D. is The James F. Holland Professor of Medicine, associate director, Education & Training for the Tisch Cancer Institute and director of the Clinical Research Education Program at the Icahn School of Medicine at Mount Sinai and the Graduate School of Biomedical Sciences. She previously served on the faculty at Memorial Sloan Kettering. Dr. Gabrilove is the recipient of a patent for the discovery of human granulocyte colony stimulating factor (G-CSF), and was the first to demonstrate that it could alleviate certain harmful effects of chemotherapy on blood cell production. She has worked closely on the development of novel therapeutics for fostering leukemic cell maturation, and has been awarded patents for two additional drugs, approved by the FDA, for the treatment of myeloid leukemia. She is a member of the American Society of Clinical Investigation, has served as a member of the Editorial Boards for the journal Blood, UpToDate, Clinical Cancer Research & Leukemia; and on the FDA Advisory Committee for approval of Biologics, among others. She has also served as an elected councilor on the executive committee for the American Society of Hematology. Dr. Gabrilove graduated from Icahn School of Medicine at Mount Sinai where she held the highest academic standing in the graduating medical school class.

Bernie Garil is a retired investment adviser and broker-dealer executive and former president of OpCap Advisors, a subsidiary of Oppenheimer Capital. He is a director or trustee of 16 investment companies for which UBS Global Asset Management (Americas) Inc. serves as investment advisor, sub-advisor, or manager, and is a member of the Audit and Nominating committees of each of the funds. Garil is a member of the board of directors, Chairman of the Examining Committee, and a member of Trust Investment and Operating committees of OFI Trust Company. Since 1976, Garil has been a volunteer for The Leukemia & Lymphoma Society as a donor, past member of the National Board of Directors (1987-1995), a trustee of the New York City chapter (1976-1995) and president of the chapter (1982-1985). He graduated from Brooklyn College with a bachelor of science degree in accounting and did graduate work in finance at American University. Garil currently serves on the Brooklyn College Foundation and works on investment issues at UBS and OFI Trust Company. 

John Greene is senior vice president of Customer Centric Engineering and Site Reliability Engineering at Salesforce, a US cloud computing company headquartered in San Francisco, CA. Greene is a hands-on technical executive, with a passion for building, growing, coaching and managing high caliber, motivated teams in enterprise. His worldwide team ensures customer success by triaging, troubleshooting, debugging, and proposing fixes to complex customer issues and incidents on the Salesforce platform. He previously spent six years providing and managing enterprise technical support at BEA/WebLogic and three years running support and community for an online virtual world. John received his bachelor’s degree in computer and information sciences in 1993 from UMass. Greene is an acute myeloid leukemia survivor and was given a 35%-40% chance to live five years when he was diagnosed in 2010. After several rounds of chemotherapy and a stem-cell transplant in 2011, he is cancer free. Greene has led Salesforce's participation in Light the Night since 2011, raising more than $4 million nationally for The Leukemia & Lymphoma Society. Greene is an avid Phish and Grateful Dead fan and currently plays keyboards in Chum, California's premiere Phish tribute band.

Francie Heller is a director at Arabesque Asset Management USA, a firm that pioneered a new approach to asset management by integrating ESG big data with quantitative strategies. She has over 30 years of financial experience spanning both the public and private sectors. Prior to Arabesque Asset Management, she was a managing partner at Heller Advisory, an alternative asset placement agent. Before that, she was a managing director at Houlihan Lokey Investment Bank and prior to that, she was a managing director at Chilton Investment Company. She has also served as senior managing director and global head of the Pension, Endowment and Foundation Services Group at Bear Stearns and Co, Inc. She was president of MBIA Municipal Investors Service Corporation (MISC) where she created and ran all aspects of the government investment management business. Heller was also an education director in a New York public school for several years. She currently serves on several boards including Big Picture Learning and Furman University. Heller graduated from Boston University with a BS and earned a master’s equivalent degree from the University of Georgia and a professional diploma (PD) from Fordham University. She holds certificates from Columbia University, Stanford University and Harvard University Executive Education programs. Heller holds her FINRA series 7 and 63 licenses. She is also a certified mediator.

Michelle Le Beau, Ph.D., is the Arthur and Marian Edelstein Professor of hematology/oncology at the University of Chicago, and director of the University of Chicago Medicine Comprehensive Cancer Center. In her role as director of the Comprehensive Cancer Center, an NCI-designated Cancer Center, Dr. Le Beau oversees cancer research, education and outreach programs. She has expertise in developing research teams, and advancing multidisciplinary and transdisciplinary research. Dr. Le Beau received her doctorate in pathology and genetics from the University of Illinois. She completed her postdoctoral training at the University of Chicago. She is an accomplished cancer geneticist with expertise in improving the diagnosis and treatment of blood cancers. Dr. Le Beau is a member of the executive committee of the American Society of Hematology, and serves on the National Cancer Policy Forum of the Institute of Medicine (National Academy of Sciences), as well as the immediate Past President of the Association of American Cancer Institutes, and a previous member of the board of directors of the American Association for Cancer Research.

Ruben A. Mesa, M.D., is director of the Mays Cancer Center, the newly named home to the UT Health San Antonio MD Anderson Cancer Center, a National Cancer Institute-designated Cancer Center. Dr. Mesa is a professor and holds the Mays Family Foundation Distinguished University presidential chair. Dr. Mesa has been principal investigator or co-principal investigator in more than 70 clinical trials for patients with myeloid disorders and played a lead role in various FDA approvals. He has been a funded investigator from the National Cancer Institute throughout his career and currently is Co-Principal Investigator of the NCI Program Project Grant Funded Myeloproliferative Neoplasms Research Consortium where he co-leads the clinical trial consortium. He also served as the Chair of the Arizona Cancer Coalition which oversees the Arizona Cancer Control Plan and worked with the Arizona Department of Health Services in advocating for Cancer in the State of Arizona. Dr. Mesa plays a range of leadership roles with the American Society of Hematology, and is chair of the Standing Science and Education Committee for the International Society of Hematology. Dr. Ruben completed his undergraduate training in nuclear engineering and physiology at University of Illinois and attended Mayo Medical School in Rochester, MN, where he completed his internal medicine residency and hematology & medical oncology fellowship. He was then on the faculty of the Mayo Clinic in hematology and later selected as deputy director of the Mayo Clinic Cancer Center from 2012-2017.

Ted Moroz has over 25 years of professional experience specializing in retail and logistics management. He became President of The Beer Store (TBS) and Brewers Distributor Ltd. in 2009 where he is responsible for managing all aspects of the business and works closely with the LLS’s committed supporter of 33 years, United Food and Commercial Workers (UFCW). Prior to this role, he has held multiple leadership roles including Vice President, Retail and Vice President, Logistics. During his tenure at TBS, he served on several committees and continues to be an active member of the Retail Council of Canada where he has served on the executive roundtable. Notably, he is a leader of the largest bottle drive in Ontario, raising over $13 million for leukemia research. Ted is Chair of LLS Canada’s Board of Directors. In 2015, he was awarded the Laurdentain University Alumni Award, which recognized his volunteer work with nonprofits. He received his Master’s degree in political science from Carleton University in Ottawa, Ontario in 1988.

Lynne F. O'Brien worked as a policy analyst with the White House Cancer Moonshot office under former Vice President, Joe Biden. Previously, she worked as director of the Washington government affairs office of DuPont Merck, working with members of Congress on issues involving the U.S. Food and Drug Administration, tax legislation, and health care reform. She started her career in D.C. with Williams and Jensen, a law firm in Washington, DC, focusing on healthcare clients. She is on the board of the Potomac School in McLean Virginia and member of Princeton's Alumni Schools Committee. She was formerly on the board of the National Organization for Fetal Alcohol Syndrome. O'Brien graduated cum laude from Princeton with a degree in political science and earned her law degree from Georgetown University Law Center.

Marla S. Persky retired as senior vice president and general counsel of Boehringer Ingelheim USA Corporation in 2013. She launched WOMN LLC, a company dedicated to helping women succeed in the private practice of law by increasing their knowledge of and acuity with the “business of law.” Through years of mentoring, she has shared her experience and observations with other attorneys and professionals to assist them in building valued, inclusive legal departments, career development and achieving business excellence. Persky’s leadership and efforts to improve diversity and inclusion in the legal profession have been recognized by elite organizations such as the Lawyer’s Collaborative for Diversity and the Connecticut Appleseed Foundation. She was recognized as one of the ten most innovative in-house counsel for her strategy and efforts to increase the opportunities and visibility of women in high profile litigation.

Donald Proctor is the founder and CEO of Bk97 Digital, providing advisory services to companies and government agencies on product strategy, innovation, technology, policy and cybersecurity. Don was previously a senior vice president at Cisco Systems Inc. As the leader of Cisco's Cybersecurity Task Force, he worked with worldwide government leaders in defense, civilian agencies, and the intelligence community to advance the safety, privacy, and integrity of their critical network infrastructure. He serves as chair of the advisory board of the Lawrence Hall of Science and is a member of the advisory board for the national College Promise Campaign. A graduate of the University of California, Berkeley, Proctor is also part of the professional faculty in the Management of Technology graduate program at UC Berkeley's Haas School of Business and formerly taught in the UC Berkeley Extension Telecommunications Engineering certification program. 

Robert Rosen is a managing member of Greyhawke Capital Advisors LLC, a Greenwich, Connecticut-based company which invests capital in, and applies management expertise to, selected investment opportunities generally involving net leased real estate properties. Since 2012, he has also served as an independent director of KLS Diversified, a hedge fund specializing in trading multiple debt strategies. Prior to this role, he was chief executive officer and at Odin Management Company, LP and Newkirk Limited Partnership. He has also practiced real estate and securities law as a senior partner at Hertzog, Calamari & Gleason and Rosen, Hacker & Nierenberg. Rosen is a graduate of Columbia Law School where he was a Harlan Fiske Stone Scholar. He graduated cum laude with departmental honors in political science from the University of Massachusetts. Rosen is a member of the Dean’s Council at Columbia Law School and the Advisory Board of the Richman Center at Columbia University for Business, Law and Public Policy.

Dr. Steven T. Rosen is the Provost, Chief Scientific Officer and Director of the Cancer Center for the City of Hope. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr. Rosen completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute. He served as the director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine from 1989-2014. Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. Dr. Rosen has received numerous grant awards and contracts and has published more than 300 scientific papers. Dr. Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996), recognition from the Woman's Board of Northwestern Memorial Hospital for Compassionate Care (1996), and Israel Cancer Research Fund, Man of Distinction Award (2011). He is acknowledged in Best Doctors in America and Best Doctors in Chicago. 

Jeff Sachs is the North American managing director of Jones Lang LaSalle’s Hotels and Hospitality Strategic Advisory and Asset Management Group. Before joining JLL, Sachs was a founding partner of Strategic Advisory Group, which was acquired by JLL in early 2016. Prior to forming Strategic Advisory Group in 1998, he was the national director of the Public Assembly Consulting Practice and the southeast director of the Hospitality Practice for Ernst & Young. He earned a bachelor’s and master’s degree in accounting from the University of Iowa. Sachs has been a volunteer with LLS since 2005, one year after surviving a diagnosis of acute myeloid leukemia (AML).

Ken Schwartz is a transaction advisory services partner with Ernst & Young LLP. He has been providing services to both private equity and corporate acquirers for the past ten years. Schwartz's experience includes complex, cross-border mergers, acquisitions, divestitures and recapitalizations. He has led teams working on transactions ranging from $5 million to more than $25 billion. Schwartz is a certified public accountant with more than 17 years of experience. He earned his bachelor's degree from the State University of New York at Albany. He is a member of the American Institute of Certified Public Accountants and the Long Island chapter of the New York State Society of Certified Public Accountants. 

Keith S. White, CEO of ParkerWhite Brand Interactive, a San Diego branding and digital marketing agency, brings more than 20 years of brand development, advertising, digital marketing, and sales management experience to the agency. Throughout his career, Keith White, a multi-disciplinary marketing professional, has built powerful consumer and trade brands in the marketplace and has successfully launched and grown many well-known consumer brands. He has been the lead brand strategist on brands like Star Trac Fitness, DJO, Zimmer Medical, Next Proteins, Red Bull, Hansen’s Natural and ADT, where he led the corporate brand marketing, strategic planning, marketing research, web development and lead generation within the highly competitive medical device and healthy lifestyle industries. His undergraduate work started at Auburn University in the sciences, and he completed his bachelor degree in communications at the University of California, San Diego.